• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Fusaric acid decreases p53 expression by altering promoter methylation and m6A RNA methylation in human hepatocellular carcinoma (HepG2) cells.非病毒酸通过改变人肝癌(HepG2)细胞启动子甲基化和 m6A RNA 甲基化来降低 p53 表达。
Epigenetics. 2021 Jan;16(1):79-91. doi: 10.1080/15592294.2020.1788324. Epub 2020 Jul 7.
2
Ibuprofen promotes p75 neurotrophin receptor expression through modifying promoter methylation and N6-methyladenosine-RNA-methylation in human gastric cancer cells.布洛芬通过改变人胃癌细胞启动子甲基化和 N6-甲基腺苷 RNA 甲基化促进 p75 神经营养因子受体的表达。
Bioengineered. 2022 Jun;13(6):14595-14604. doi: 10.1080/21655979.2022.2092674.
3
Fusaric acid-induced promoter methylation of DNA methyltransferases triggers DNA hypomethylation in human hepatocellular carcinoma (HepG2) cells.刀豆氨酸诱导的 DNA 甲基转移酶启动子甲基化导致人肝癌(HepG2)细胞中的 DNA 低甲基化。
Epigenetics. 2019 Aug;14(8):804-817. doi: 10.1080/15592294.2019.1615358. Epub 2019 May 16.
4
Fusaric acid induces hepatic global m6A RNA methylation and differential expression of m6A regulatory genes - a pilot study. Fusaric 酸诱导肝内全局 m6A RNA 甲基化和 m6A 调控基因的差异表达——一项初步研究。
Epigenetics. 2022 Jun;17(6):695-703. doi: 10.1080/15592294.2021.1975937. Epub 2021 Sep 13.
5
mA modification impacts hepatic drug and lipid metabolism properties by regulating carboxylesterase 2.mA 修饰通过调节羧酸酯酶 2 影响肝脏药物和脂质代谢特性。
Biochem Pharmacol. 2021 Nov;193:114766. doi: 10.1016/j.bcp.2021.114766. Epub 2021 Sep 16.
6
METTL3 and ALKBH5 oppositely regulate mA modification of mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes.METTL3 和 ALKBH5 对 mRNA 的 mA 修饰起相反调控作用,从而决定了低氧/复氧处理的心肌细胞的命运。
Autophagy. 2019 Aug;15(8):1419-1437. doi: 10.1080/15548627.2019.1586246. Epub 2019 Mar 17.
7
RNA m6A modification, signals for degradation or stabilisation?RNA的m6A修饰:降解信号还是稳定信号?
Biochem Soc Trans. 2024 Apr 24;52(2):707-717. doi: 10.1042/BST20230574.
8
m6A Regulators in Human Adipose Tissue - Depot-Specificity and Correlation With Obesity.m6A 调节剂在人体脂肪组织中的分布特异性及其与肥胖的相关性。
Front Endocrinol (Lausanne). 2021 Dec 7;12:778875. doi: 10.3389/fendo.2021.778875. eCollection 2021.
9
RNA m6A methylation regulators in sepsis.脓毒症中的 RNA m6A 甲基化调节因子。
Mol Cell Biochem. 2024 Sep;479(9):2165-2180. doi: 10.1007/s11010-023-04841-w. Epub 2023 Sep 2.
10
Upregulation of METTL3 expression and m6A RNA methylation in placental trophoblasts in preeclampsia.上调 METTL3 在子痫前期胎盘滋养细胞中的表达和 m6A RNA 甲基化。
Placenta. 2021 Jan 1;103:43-49. doi: 10.1016/j.placenta.2020.10.016. Epub 2020 Oct 13.

引用本文的文献

1
The therapeutic potential of RNA m(6)A in lung cancer.RNA m(6)A在肺癌中的治疗潜力。
Cell Commun Signal. 2024 Dec 31;22(1):617. doi: 10.1186/s12964-024-01980-5.
2
The crosstalk between alternative splicing and circular RNA in cancer: pathogenic insights and therapeutic implications.剪接异构体与环状 RNA 在癌症中的相互作用:发病机制见解和治疗意义。
Cell Mol Biol Lett. 2024 Nov 16;29(1):142. doi: 10.1186/s11658-024-00662-x.
3
RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy.RNA m6A 修饰在铁死亡中的作用:对推进肿瘤免疫治疗的启示。
Mol Cancer. 2024 Sep 28;23(1):213. doi: 10.1186/s12943-024-02132-6.
4
P53-associated lncRNAs regulate immune functions and RNA-modifiers in gastric cancer.P53相关的长链非编码RNA在胃癌中调节免疫功能和RNA修饰因子。
Heliyon. 2024 Jul 26;10(15):e35228. doi: 10.1016/j.heliyon.2024.e35228. eCollection 2024 Aug 15.
5
Elucidating the role of nicotinamide N-methyltransferase-p53 axis in the progression of chronic kidney disease.阐明烟酰胺 N-甲基转移酶-p53 轴在慢性肾脏病进展中的作用。
PeerJ. 2023 Nov 8;11:e16301. doi: 10.7717/peerj.16301. eCollection 2023.
6
METTL14‑mediated RNA methylation in digestive system tumors.METTL14 介导的消化系统肿瘤中的 RNA 甲基化。
Int J Mol Med. 2023 Sep;52(3). doi: 10.3892/ijmm.2023.5289. Epub 2023 Aug 4.
7
Multilevel regulation of N-methyladenosine RNA modifications: Implications in tumorigenesis and therapeutic opportunities.N-甲基腺苷RNA修饰的多级调控:对肿瘤发生的影响及治疗机会
Genes Dis. 2022 Sep 7;10(5):1969-1981. doi: 10.1016/j.gendis.2022.08.018. eCollection 2023 Sep.
8
RNA m A methylation in cancer.癌症中的 RNA mA 甲基化。
Mol Oncol. 2023 Feb;17(2):195-229. doi: 10.1002/1878-0261.13326. Epub 2022 Nov 6.
9
Ibuprofen promotes p75 neurotrophin receptor expression through modifying promoter methylation and N6-methyladenosine-RNA-methylation in human gastric cancer cells.布洛芬通过改变人胃癌细胞启动子甲基化和 N6-甲基腺苷 RNA 甲基化促进 p75 神经营养因子受体的表达。
Bioengineered. 2022 Jun;13(6):14595-14604. doi: 10.1080/21655979.2022.2092674.
10
Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours.N6-甲基腺苷甲基化调节剂在消化系统肿瘤药物治疗中的作用
Front Pharmacol. 2022 Jun 9;13:908079. doi: 10.3389/fphar.2022.908079. eCollection 2022.

本文引用的文献

1
N-methyladenosine mediates arsenite-induced human keratinocyte transformation by suppressing p53 activation.N6-甲基腺苷通过抑制 p53 激活介导亚砷酸盐诱导的人角质形成细胞转化。
Environ Pollut. 2020 Apr;259:113908. doi: 10.1016/j.envpol.2019.113908. Epub 2020 Jan 7.
2
Landscape and Regulation of mA and mAm Methylome across Human and Mouse Tissues.人类和小鼠组织中 mA 和 mAm 甲基组的景观和调控。
Mol Cell. 2020 Jan 16;77(2):426-440.e6. doi: 10.1016/j.molcel.2019.09.032. Epub 2019 Oct 29.
3
Cyclophosphamide Regulates N6-Methyladenosine and m6A RNA Enzyme Levels in Human Granulosa Cells and in Ovaries of a Premature Ovarian Aging Mouse Model.环磷酰胺调节人颗粒细胞和卵巢早衰小鼠模型卵巢中的N6-甲基腺苷和m6A RNA酶水平。
Front Endocrinol (Lausanne). 2019 Jun 27;10:415. doi: 10.3389/fendo.2019.00415. eCollection 2019.
4
Fusaric acid-induced promoter methylation of DNA methyltransferases triggers DNA hypomethylation in human hepatocellular carcinoma (HepG2) cells.刀豆氨酸诱导的 DNA 甲基转移酶启动子甲基化导致人肝癌(HepG2)细胞中的 DNA 低甲基化。
Epigenetics. 2019 Aug;14(8):804-817. doi: 10.1080/15592294.2019.1615358. Epub 2019 May 16.
5
The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA.m6A 去甲基酶 FTO 通过调节 USP7 mRNA 的 m6A 水平促进肺癌细胞的生长。
Biochem Biophys Res Commun. 2019 May 7;512(3):479-485. doi: 10.1016/j.bbrc.2019.03.093. Epub 2019 Mar 21.
6
RNA-binding protein YTHDF3 suppresses interferon-dependent antiviral responses by promoting FOXO3 translation.RNA 结合蛋白 YTHDF3 通过促进 FOXO3 翻译来抑制干扰素依赖的抗病毒反应。
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):976-981. doi: 10.1073/pnas.1812536116. Epub 2018 Dec 27.
7
An N-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells.p53 前体 mRNA 中转录密码子 273 处的 N6-甲基腺苷促进 R273H 突变蛋白的表达和癌细胞的耐药性。
Biochem Pharmacol. 2019 Feb;160:134-145. doi: 10.1016/j.bcp.2018.12.014. Epub 2018 Dec 19.
8
Circadian Clock Regulation of Hepatic Lipid Metabolism by Modulation of mA mRNA Methylation.生物钟通过调节 mA mRNA 甲基化调控肝脏脂质代谢。
Cell Rep. 2018 Nov 13;25(7):1816-1828.e4. doi: 10.1016/j.celrep.2018.10.068.
9
Human ALKBH3-induced mA demethylation increases the CSF-1 mRNA stability in breast and ovarian cancer cells.人类 ALKBH3 诱导的 mA 去甲基化增加乳腺癌和卵巢癌细胞中的 CSF-1 mRNA 稳定性。
Biochim Biophys Acta Gene Regul Mech. 2019 Jan;1862(1):35-46. doi: 10.1016/j.bbagrm.2018.10.008. Epub 2018 Oct 17.
10
Cross-talk among writers, readers, and erasers of mA regulates cancer growth and progression.作家、读者和 mA 橡皮擦之间的串扰调节癌症的生长和进展。
Sci Adv. 2018 Oct 3;4(10):eaar8263. doi: 10.1126/sciadv.aar8263. eCollection 2018 Oct.

非病毒酸通过改变人肝癌(HepG2)细胞启动子甲基化和 m6A RNA 甲基化来降低 p53 表达。

Fusaric acid decreases p53 expression by altering promoter methylation and m6A RNA methylation in human hepatocellular carcinoma (HepG2) cells.

机构信息

Discipline of Medical Biochemistry and Chemical Pathology, School of Laboratory Medicine and Medical Science, College of Health Sciences, Howard College Campus, University of KwaZulu-Natal , Durban, South Africa.

出版信息

Epigenetics. 2021 Jan;16(1):79-91. doi: 10.1080/15592294.2020.1788324. Epub 2020 Jul 7.

DOI:10.1080/15592294.2020.1788324
PMID:32631113
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7889137/
Abstract

Fusaric acid (FA) is a food-borne mycotoxin that mediates toxicity with limited information on its epigenetic properties. p53 is a tumour suppressor protein that regulates cell cycle arrest and apoptotic cell death. The expression of p53 is regulated transcriptionally by promoter methylation and post-transcriptionally by N-6-methyladenosine (m6A) RNA methylation. We investigated the effect of FA on p53 expression and its epigenetic regulation via promoter methylation and m6A RNA methylation in human hepatocellular carcinoma (HepG2) cells. HepG2 cells were treated with FA [0, 25, 50, 104, and 150 µg/ml; 24 h] and thereafter, DNA, RNA, and protein was isolated. Promoter methylation and expression of p53 was measured using qPCR and Western blot. RNA immuno-precipitation was used to determine m6A- levels. The expression of m6A methyltransferases ( and ), demethylases ( and ), and readers ( and ) were measured using qPCR. FA induced promoter hypermethylation ( < 0.0001) and decreased expression ( < 0.0001). FA decreased m6A- levels ( < 0.0001) by decreasing ( < 0.0001) and ( < 0.0001); and suppressed expression of ( < 0.0001), ( < 0.0001), and ( < 0.0001) that ultimately reduced p53 translation ( < 0.0001). Taken together, the data shows that FA epigenetically decreased p53 expression by altering its promoter methylation and m6A RNA methylation in HepG2 cells. This study reveals a mechanism for p53 regulation by FA and provides insight into future therapeutic interventions.

摘要

伏马菌素(FA)是一种食源性病原体毒素,其在表观遗传学特性方面的信息有限。p53 是一种肿瘤抑制蛋白,可调节细胞周期停滞和细胞凋亡。p53 的表达受启动子甲基化和 N-6-甲基腺苷(m6A)RNA 甲基化的转录后调控。我们研究了 FA 对人肝癌(HepG2)细胞中 p53 表达及其表观遗传调控的影响,包括启动子甲基化和 m6A RNA 甲基化。用 FA [0、25、50、104 和 150μg/ml;24 h]处理 HepG2 细胞,然后分离 DNA、RNA 和蛋白质。用 qPCR 和 Western blot 检测启动子甲基化和 p53 的表达。用 RNA 免疫沉淀法测定 m6A-水平。用 qPCR 检测 m6A 甲基转移酶(、和)、去甲基酶(和)和读码器(和)的表达。FA 诱导 启动子超甲基化(<0.0001)并降低 表达(<0.0001)。FA 通过降低 (<0.0001)和 (<0.0001)降低 m6A-水平(<0.0001);并抑制 (<0.0001)、(<0.0001)和 (<0.0001)的表达,最终降低 p53 翻译(<0.0001)。总之,数据表明 FA 通过改变 HepG2 细胞中 p53 的启动子甲基化和 m6A RNA 甲基化,在表观遗传学上降低了 p53 的表达。该研究揭示了 FA 调节 p53 的机制,并为未来的治疗干预提供了思路。